Advertisement

Topics

Mersana Adds to Antibody Drug Conjugate (ADC) Intellectual Property Portfolio with Issuance of EP Patent

07:00 EST 9 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Mersana Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Fleximer® technology, today announced that it was a...

Other Sources for this Article

For Mersana Therapeutics, Inc.
Media Contact
Paul Kidwell, 617-680-1088
paulkidwell@comcast.net
or
Investors Contact
Stern Investor Relations, Inc.
Christina Tartaglia, 212-362-1200
christina@sternir.com

NEXT ARTICLE

More From BioPortfolio on "Mersana Adds to Antibody Drug Conjugate (ADC) Intellectual Property Portfolio with Issuance of EP Patent"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...